Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website

BRAINTREE, Mass., Aug. 1, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced fiscal year 2017 first quarter financial results are available on its Investor relations website.

The Company is posting this press release and additional commentary to be discussed on the webcast entitled Comments on 1st Quarter Fiscal 2017 Results to its Investor Relations website. 

Direct link to Earnings Release FY17 Q1: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzQ1NDEzfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636051357898808766.  

Direct link to Comments on 1st Quarter Fiscal 2017 Results: http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzQ1NDM1fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636051357898808766.

As previously announced, the Company will host a conference call with investors and analysts to discuss and answer questions about the results at 8:00am Eastern Time on August 1, 2016. A live webcast of the call can be accessed on Haemonetics' investor relations website.

Direct link to Conference Call Webcast: http://edge.media-server.com/m/p/vnuvfpge

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

INVESTOR CONTACT:Gerry Gould, VP-Investor Relations(781) 356-9402 [email protected] 

MEDIA CONTACT:Sandra Jesse, Executive VP(781) 356-9253 [email protected]   

Logo - http://photos.prnewswire.com/prnh/20160405/351568LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/haemonetics-1st-quarter-fiscal-2017-earnings-release-available-on-investor-relations-website-300306560.html

SOURCE Haemonetics Corporation